
Janssen Reports Results of Tremfya (guselkumab) in P-IIb (QUASAR) Induction Study for the Treatment of Active Ulcerative Colitis
Shots:
- The P-IIb (QUASAR) induction study evaluates Tremfya (200/400mg, IV) vs PBO in 313 patients with UC with inadequate response/intolerance to conventional therapies or advanced therapies
- The results showed that patients achieved clinical response @12wk. (61.4%/60.7% vs 27.6%), clinical remission rates (25.7%/25.2% vs 9.5%), symptomatic remission rates (50.5%/47.7% vs 20%), endoscopic improvement rates (30.7%/30.8% vs 12.4%), histo-endoscopic mucosal improvement (19.8/27.1% vs 8.6%), endoscopic normalization rates (17.8%/14% vs 6.7%) & safety data were consistent with safety profile for Tremfya
- Tremfya is approved in the US, Canada, Japan, EU & other countries globally for PsO & active PsA
Ref: PR Newswire | Image: Medical Dialogues
Click here to read the full press release

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com